Please assess the completion status of the following clinical trial:

Trial Title: The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Mothers may be eligible for this study if they:~* Receive prenatal care at King Edward VIII Hospital, Durban, or St. Mary's Hospital, Marianhill, South Africa; or polyclinics in Chitungwiza District, Zimbabwe.~* Are pregnant for at least 30 weeks before giving birth.~* Are at least 18 years of age.~* Are HIV-positive by 2 ELISA tests.~* Have no serious current or previous problems in pregnancy (e.g., seizures).~* Have a fixed home and/or work address.~* Plan to deliver the baby at a hospital or clinic where the study is based.~* Plan to breast-feed their babies.~* Infants may be eligible for this study if they:~* Are born to women participating in this study.~* Weigh at least 2.5 kg at birth.~* Begin breast-feeding by 48 hours.~Exclusion Criteria~Mothers will not be eligible for this study if they:~* Have AIDS or any other serious illness.~* Are using illegal drugs or have been using alcohol for a long time.~* Are sensitive to NVP.~* Have taken any nonnucleoside reverse transcriptase inhibitors in the past.~* Are using rifampin, rifabutin, ketoconazole, macrolides, or cimetidine.~* Infants will not be eligible for this study if they:~* Have jaundice (yellowing of the skin and whites of eyes) that requires a blood transfusion.~* Have any serious or life-threatening condition(s).

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).